Imidafenacin, An Orally Active Muscarinic Receptor Antagonist, Improves Pulmonary Function In Patients With Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled 3×3 Crossover Phase II Trial

BACKGROUND: Although long-acting muscarinic receptor antagonists are central to the management of chronic obstructive pulmonary disease (COPD), inhaled medicines may have technical difficulty in some patients and adherence barriers. METHODS: A multicenter, randomized, double-blind, placebo-controlle...

Descripción completa

Detalles Bibliográficos
Autores principales: Machida, Kentaro, Kawayama, Tomotaka, Kinoshita, Masaharu, Ichinose, Masakazu, Tsuda, Tohru, Takata, Shohei, Koto, Hiroshi, Yoshida, Makoto, Ashihara, Yoshinori, Kawashima, Masaru, Suna, Hideaki, Inoue, Hiromasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757323/
https://www.ncbi.nlm.nih.gov/pubmed/31571853
http://dx.doi.org/10.2147/COPD.S223002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757323/
https://www.ncbi.nlm.nih.gov/pubmed/31571853
http://dx.doi.org/10.2147/COPD.S223002

Ejemplares similares